+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis



Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis



Oncology Reports 10(4): 803-811



The term "malignant mesenchymoma" (MM) has traditionally been applied to a group of malignant soft tissue tumors that are characterized by the presence of two or more different mesenchymal tissue components in the same neoplasm. Currently, sarcomas with multilineage differentiation fulfilling the criteria of MM tend to be diagnosed as specific sarcomas with heterologous differentiation (e.g., de-differentiated liposarcoma) rather than MM; however, some cases of these tumors are difficult to classify. The purpose of this study was to analyze the clinicopathological and immunohistochemical features of these unclassifiable tumors, the so-called MM, and to determine whether some parameters are a useful adjunct for the classification of these tumors from the viewpoint of clinical outcome. Twelve cases of so-called MM were investigated retrospectively. The patients (six male, six female) ranged in age from 6 to 71 years (mean 48 years). Tumor size ranged from 3 to 20 cm (mean 13 cm). Tumor locations included the retroperitoneum (five cases), abdominal wall (two), thigh (two), forearm (one), lung (one), and parotid gland (one). The differentiated mesenchymal components were rhabdomyosarcomatous (RMS) (six cases), liposarcomatous (five), chondrosarcomatous (five), osteosarcomatous (five), or leiomyosarcomatous (four). Follow-up in all cases (range 4-129 months; mean 36 months) showed a 67% local recurrence rate, a 33% metastatic rate, and a 50% disease-related mortality. The patients who were under 40 years of age or who had an RMS component showed significantly worse survival than did patients in the other groups. The other mesenchymal components showed no significant correlation with survival. The immunophenotypes of p53 and mdm2 were almost identical between the two mesenchymal components in each case; however, there was no significant correlation between either of these immunophenotypes and the clinical outcome. None of the other factors (gender, tumor site, tumor size, or MIB-1-labeling index) was found to be a statistically significant prognostic indicator. In conclusion, a patient age under 40 years and the presence of an RMS component appear to be poor prognostic indicators of survival in patients with so-called MM, and to be a useful adjunct for the classification of these tumors.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011206301

Download citation: RISBibTeXText

PMID: 12792727


Related references

Prognostic factors in ovarian carcinosarcoma: A clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 37(5): 427-436, 2000

Prognostic factors in desmoid-type fibromatosis: a clinicopathological and immunohistochemical analysis of 46 cases. Pathology 42(2): 147-150, 2010

Prognostic factors in malignant germ cell tumors of the ovary a clinicopathological analysis. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 518, 1990

Clinicopathological Features and Prognostic Factors of Malignant Melanoma: A Retrospective Analysis of Thai Patients in Ramathibodi Hospital. Journal of the Medical Association of Thailand 98(8): 820-827, 2015

Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. Journal of Gastrointestinal Surgery 9(3): 418-429, 2005

Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Research 52(8): 2325-2328, 1992

So-called rhabdomyosarcoma (malignant mesenchymoma) of the middle ear. Pathologica 67(965-966): 151-157, 1975

Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica 96(6): 475-478, 2004

The relation between soft tissue malignant mesenchymoma and other sarcomas--a case report of malignant mesenchymoma of the tunica vaginalis of the left testis. Zhonghua Zhong Liu Za Zhi 6(3): 229-230, 1984

The relation between the soft tissue malignant mesenchymoma and the other sarcomas a case report of malignant mesenchymoma of tunica vaginalis of the left testis. Zhonghua Zhongliu Zazhi 6(3): 229-230, 1984

Malignant mesenchymoma of the prostate: immunohistochemical and ultrastructural observations. Ultrastructural Pathology 18(4): 449-456, 1994

A clinicopathological study on rectal carcinoid with special reference to immunohistochemical factors of malignant potential. Journal of the Japan Society of Coloproctology 50(3): 163-176, 1997

Immunohistochemical Analysis of p53 in Colorectal Cancer Regarding Clinicopathological Correlation and Prognostic Significance. Journal Of Surgical Oncology. 58(2): 125-128, 1995

Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. Case Reports in Pathology 2012: 749898, 2012

Malignant dermatofibroma clinicopathological, immunohistochemical, and molecular analysis of seven cases. Modern Pathology 26(2): 256-267, 2013